Get started
Author

Saima Noor Hassan

Observed names: Hassan, Saima, S Hassan, S. Hassan, Saima Hassan, Saima N. Hassan
Observed institutions: Mount Sinai Hospital, Sunnybrook Health Science Centre, University of Ottawa, Oregon Health & Science University, Jewish General Hospital, Vancouver General Hospital, Ontario Tech University, Lebanon VA Medical Center, Centre Hospitalier de l’Université de Montréal, NSABP Foundation, Université Laval, Ottawa Hospital Research Institute, Lady Davis Institute for Medical Research, Canadian Cancer Trials Group, Odette Cancer Centre, Institut du cancer de Montréal, McGill University, Concordia University, Université de Montréal, Penn State Milton S. Hershey Medical Center, The University of Texas Southwestern Medical Center
ORCID: 0000-0003-0232-2807
Observed ORCID: 0000-0003-0232-2807
OpenAlex ID: A5066358109
CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis and enhances the efficacy of anti‐VEGF treatment or docetaxel in a transgenic mouse model
2010 · Saima Hassan, Marguerite Buchanan, et al. · International Journal of Cancer · 126
An integrated genomic approach identifies ARID1A as a candidate tumor-suppressor gene in breast cancer
2011 · A Mamo, L Cavallone, et al. · Oncogene · 125
Prognostic and predictive value of circulating tumor DNA during neoadjuvant chemotherapy for triple negative breast cancer
2020 · Luca Cavallone, Adriana Aguilar-Mahecha, et al. · Scientific Reports · 95
PDF
Endoplasmic reticulum stress induces PRNP prion protein gene expression in breast cancer
2013 · Marc-André Déry, Julie Jodoin, et al. · Breast Cancer Research · 87
PDF
Tissue microarrays: emerging standard for biomarker validation
2008 · Saima Hassan, Cristiano Ferrario, et al. · Current Opinion in Biotechnology · 72
The Estrogen Receptor Cofactor SPEN Functions as a Tumor Suppressor and Candidate Biomarker of Drug Responsiveness in Hormone-Dependent Breast Cancers
2015 · Stéphanie Légaré, Luca Cavallone, et al. · Cancer Research · 62
The Influence of Tumor-Host Interactions in the Stromal Cell-Derived Factor-1/CXCR4 Ligand/Receptor Axis in Determining Metastatic Risk in Breast Cancer
2009 · Saima Hassan, Cristiano Ferrario, et al. · American Journal Of Pathology · 62
PDF
Plasma Stromal Cell–Derived Factor-1: Host Derived Marker Predictive of Distant Metastasis in Breast Cancer
2008 · Saima Hassan, Andrea Baccarelli, et al. · Clinical Cancer Research · 60
Both t-Darpp and DARPP-32 can cause resistance to trastuzumab in breast cancer cells and are frequently expressed in primary breast cancers
2009 · Sophie Hamel, Amélie Bouchard, et al. · Breast Cancer Research and Treatment · 56
Translating the role of PARP inhibitors in triple-negative breast cancer
2019 · Michèle Beniey, Takrima Haque, et al. · Oncoscience · 39
PDF
Microarrays as Validation Strategies in Clinical Samples: Tissue and Protein Microarrays
2006 · Adriana Aguilar-Mahecha, Saima Hassan, et al. · OMICS A Journal of Integrative Biology · 36
Pathway-Enriched Gene Signature Associated with 53BP1 Response to PARP Inhibition in Triple-Negative Breast Cancer
2017 · Saima Hassan, Amanda Esch, et al. · Molecular Cancer Therapeutics · 31
Pathologic Complete Response to Intralesional Interleukin-2 Therapy Associated with Improved Survival in Melanoma Patients with In-Transit Disease
2014 · Saima Hassan, Teresa M. Petrella, et al. · Annals of Surgical Oncology · 23
Sequential targeting of PARP with carboplatin inhibits primary tumour growth and distant metastasis in triple-negative breast cancer
2023 · Michèle Beniey, Audrey Hubert, et al. · British Journal of Cancer · 21
PDF
Clinical features and outcomes of 20 patients with abdominopelvic desmoplastic small round cell tumor
2016 · F.A. Angarita, S. Hassan, et al. · European Journal of Surgical Oncology · 20
Abstract GS3-05: NSABP B-59/GBG-96-GeparDouze: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy with atezolizumab or placebo followed by adjuvant atezolizumab or placebo in patients with Stage II and III triple-negative breast cancer
2025 · Charles Geyer, Gong Tang, et al. · Clinical Cancer Research · 17
Expanding the Use of PARP Inhibitors as Monotherapy and in Combination in Triple-Negative Breast Cancer
2021 · Mariya Yordanova, Audrey Hubert, et al. · Pharmaceuticals · 14
PDF
The Role of the 21-Gene Recurrence Score® Assay in Hormone Receptor-Positive, Node-Positive Breast Cancer: The Canadian Experience
2022 · Mariya Yordanova, Saima Hassan · Current Oncology · 11
PDF
Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41
2023 · Priya Rastogi, Gong Tang, et al. · Breast Cancer Research and Treatment · 10
PDF
Erratum to: Pathologic Complete Response to Intralesional Interleukin-2 Therapy Associated with Improved Survival in Melanoma Patients with In-Transit Disease
2014 · Saima Hassan, Teresa M. Petrella, et al. · Annals of Surgical Oncology · 10
PDF
Phenotypic and proteomic alterations of acquired trastuzumab resistance
2005 · D. Tripathy, S. Hassan, et al. · Journal of Clinical Oncology · 9
Leveraging PARP-1/2 to Target Distant Metastasis
2024 · Mallory I. Frederick, Djihane Abdesselam, et al. · International Journal of Molecular Sciences · 6
PDF
Exactis-03: A phase I trial of the combination of olaparib and navitoclax in women with high grade serous ovarian cancer and triple negative breast cancer.
2023 · Helen Mackay, Anne-Marie Mes-Masson, et al. · Journal of Clinical Oncology · 6
The Terry Fox Research Institute Marathon of Hope Cancer Centres Network: A pan-Canadian precision oncology initiative
2025 · Tess Aalto, Maria Abacan, et al. · Cancer Cell · 5
Targeting FEN1/EXO1 to enhance efficacy of PARP inhibition in triple-negative breast cancer
2025 · Mallory I. Frederick, Elicia Fyle, et al. · Translational Oncology · 5
Works count: 86
Citation count: 1,025
H-index: 16
I10-index: 20
Year
Topic
Type